TO investigate the inflammation of the anterior chamber after intravitreal bevacizumab injection in different ocular exudative diseases.
Methods
The study included 76 eyes from 62 consecutive patients with different ocular exudative diseases. The patients were divided into the 3 following groups: group 1 (nonproliferative diabetic retinopathy), group 2 (choroidal neovascularization secondary to age-related macular degeneration), and group 3 (macular edema with branch or central retinal vein occlusion). The study also included 32 age-matched control patients. Inflammation of the anterior chamber was examined with flare-cell photometry before and after an intravitreal injection of 1.25 mg of bevacizumab.
Results
There were no statistically significant differences between the measurements at baseline and postoperative day 1, 3, 7, or 30 in any of the groups (p>0.05).
Conclusions
The extent of inflammation in the anterior chamber did not change after intravitreal bevacizumab injection in patients with nonproliferative diabetic retinopathy, choroidal neovascularization secondary to age-related macular degeneration, or macular edema due to branch or central vein occlusion.
FerraraN., GerberH.P., Le CouterJ.The biology of VEGF and receptors. Nat Med2003; 9: 669–73.
2.
GearyC.A., JungkimS., RavikumarK., KelliherC., AchesonR.W., Hickey-DwyerM.L.Intravitreal bevacizumab in the treatment of neovascular age-related macular degeneration, 6–9 months results. Eye2008; 22: 82–6.
3.
LadasI.D., KotsolisA.I., PapakostasT.D., RouvasA.A., KaragiannisD.A., VergadosI.Intravitreal bevacizumab combined with photodynamic therapy for the treatment of occult choroidal neovascularization associated with serous pigment epithelium detachment in age-related macular degeneration. Retina2007; 27: 891–6.
4.
ByeonS.H., KwonY.A., OhH.S., KimM., KwonO.W.Short term results of bevacizumab for macular edema with retinal vein obstruction and diabetic macular edema. J Ocul Pharmacol Ther2007; 23: 387–94.
5.
Diabetic Retinopathy Clinical Research Network. A phase II randomized clinical trial of intravitreal bevacizumab for diabetic macular edema. Ophthalmology2007; 114: 1860–7.
6.
PaiS.A., ShettyR., VijayanP.B.Clinical, anatomic, and electrophysiologic evaluation following intravitreal bevacizumab for macular edema in retinal vein occlusion. Am J Ophthalmol2007; 143: 601–6.
7.
SpaideR.F., FisherY.L.Intravitreal bevacizumab treatment of proliferative diabetic retinopathy complicated by vitreous hemorrhage. Retina2006; 26: 275–8.
8.
ChilovM.N., GriggJ.R., PlayfairT.J.Bevacizumab for the treatment of neovascular glaucoma. Clin Exp Ophthalmol2007; 35: 494–6.
9.
BatiogluF., AstamN., OzmertE.Rapid improvement of retinal and iris neovascularization after a single intravitreal bevacizumab injection in a patient with central vein occlusion and neovascular glaucoma. Int Ophthalmol2008; 28: 59–61.
10.
HusainD., KimI., GauthierD.Safety and efficacy of intravitreal injection of ranibizumab in combination with verteporfin PDT on experimental choroidal neovascularization in the monkey. Arch Ophthalmol2005; 123: 509–16.
11.
RosenfeldP.J., HeierJ.S., HantsbargerG., ShamsN.Tolerability and efficacy of multiple escalating doses of ranibizumab (Lucentis) for neovascular age-related macular degeneration. Ophthalmology2006; 113: 632.
12.
Macugen AMD Study Group.Pegaptanib 1-year systemic safety results from a safety-pharmacokinetic trial in patients with neovascular age-related macular degeneration. Ophthalmology2007; 114: 1702–12.
13.
KissC., MichelsS., PragerF., WeigertG., GeitzenauerW.Evaluation of anterior chamber inflammatory activity in eyes treated with intravitreal bevacizumab. Retina2006; 26: 877–81.
14.
Tugal-TutkunI., HerbortC.P.Laser flare photometry: a noninvasive, objective, and quantitative method to measure intraocular inflammation. Int Ophthalmol Epub2009 May 9.
15.
ZaczekA., HallnosK., ZetterstromC.Aqueous flare intensity in relation to different stages of diabetic retinopathy. Eur J Ophthalmol1999; 9: 158–64.
16.
NguyenN.X., KuchleM.Aqueous flare and cells in eyes with retinal vein occlusion-correlation with retinal fluorescein angiographic findings. Br J Ophthalmol1993; 77: 280–3.
17.
KubotaT., MotomatsuK., SakamotoM., HondaT., IshibashiT.Aqueous flare in eyes with senile disciform macular degeneration: correlation with clinical stage and area of neovascular membrane. Graefes Arch Clin Exp Ophthalmol1996; 234: 285–7.
18.
BrouzasD., KoutsandreaC., MoschosM., PapadimitriouS., LadasI., ApostolopoulasM.Massive choroidal hemorrhage after intravitreal administration of bevacizumab (Avastin) for AMD followed by contralateral sympathetic ophthalmia. Clin Ophthalmol2009; 3: 457–9.
19.
InanU.U., AvciB., KusbeciT., KaderliB., AvciR., TemelS.G.Preclinical safety evaluation of intravitreal injection of full-length humanized vascular endothelial growth factor antibody in rabbit eyes. Invest Ophthalmol Vis Sci2007; 48: 1773–81.
20.
FungA.E., RosenfeldP.J., ReichelE.The international intravitreal bevacizumab safety survey: using the Internet to assess drug safety worldwide. Br J Ophthalmol2006; 90: 1344–9.
21.
CostaR.A., JorgeR., CalucciD., CardilloJ.A., MeloL.A.Jr., ScottI.U.Intravitreal bevacizumab for choroidal neovascularization caused by AMD (IBeNA Study): results of a phase 1 dose-escalation study. Invest Ophthalmol Vis Sci2006; 47: 4569–78.
22.
ShimaC., SakaguchiH., GomiF.Complications in patients after intravitreal injection of bevacizumab. Acta Ophthalmol (Copenh)2008; 86: 372–6.
23.
WickremasingheS.S., MichalovaK., GilhotraJ.Acute intraocular inflammation after intravitreal injection of bevacizumab for treatment of neovascular age-related macular degeneration. Ophthalmology2008; 115: 1911–5.
24.
GeorgopoulosM., PolakK., PragerF., PrunteC., Schmidt-ErfurthU.Characteristics of severe intraocular inflammation following intravitreal injection of bevacizumab (Avastin). Br J Ophthalmol2009; 93: 457–62.
25.
RosenfeldP.J., SchwartzS.D., BlumenkranzM.S.Maxi-mum tolerated dose of a humanized anti-vascular endothelial growth factor antibody fragment for treating neovascular age-related macular degeneration. Ophthalmology2005; 112: 1048–53.
26.
WangY., ReiD., VanderlaanM., SongA.Biological activity of bevacizumab, a humanized anti-VEGR antibody in vitro. Angiogenesis2004; 7: 335–45.
